Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CANVAS Trial Results: Better For Janssen, Lilly Or the SGLT2 Class?

Jun 14 2017

• By Mandy Jackson

Diabetes

Related Content

Invokana Adds Warnings On Amputation Risk, But Will It Give Jardiance An Edge?

May 17 2017

Merck & Co, Pfizer Ertugliflozin Combo Data Beef Up Profile

Jun 12 2017

BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim

Dec 02 2016

Related Companies

Johnson & Johnson

Johnson & Johnson

AstraZeneca PLC

Eli Lilly and Company

Boehringer Ingelheim GmbH

Merck & Co., Inc.

Pfizer Inc.

Additional Topics

Drug Safety Commercial Clinical Trials Metabolic Disorders Cardiovascular BioPharmaceutical

More from Alimentary/Metabolic

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.